BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31420937)

  • 1. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis.
    Li A; Kuderer NM; Garcia DA; Khorana AA; Wells PS; Carrier M; Lyman GH
    J Thromb Haemost; 2019 Dec; 17(12):2141-2151. PubMed ID: 31420937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
    Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
    Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
    Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
    Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
    Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
    Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
    Di Nisio M; van Es N; Carrier M; Wang TF; Garcia D; Segers A; Weitz J; Buller H; Raskob G
    J Thromb Haemost; 2019 Nov; 17(11):1866-1874. PubMed ID: 31271705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.
    Shaw J; de Wit C; Le Gal G; Carrier M
    J Thromb Haemost; 2017 May; 15(5):925-930. PubMed ID: 28296069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis.
    Elsebaie MAT; van Es N; Langston A; Büller HR; Gaddh M
    J Thromb Haemost; 2019 Apr; 17(4):645-656. PubMed ID: 30690830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
    Howe Z; Naville-Cook C; Cole D
    J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis.
    Vasanthamohan L; Boonyawat K; Chai-Adisaksopha C; Crowther M
    J Thromb Haemost; 2018 Jul; 16(7):1288-1295. PubMed ID: 29772108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer.
    Wang Y; Wang M; Ni Y; Liang Z
    Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Otten HM; Rutjes AW
    Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.
    Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S
    J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Oral Anticoagulant Therapy for Cancer-Associated Venous Thromboembolism in Routine Clinical Practice.
    Ogino Y; Ishigami T; Minamimoto Y; Kimura Y; Akiyama E; Okada K; Matsuzawa Y; Maejima N; Iwahashi N; Hibi K; Kosuge M; Ebina T; Ishikawa T; Tamura K; Kimura K
    Circ J; 2020 Jul; 84(8):1330-1338. PubMed ID: 32624519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.
    Kahn SR; Morrison DR; Diendéré G; Piché A; Filion KB; Klil-Drori AJ; Douketis JD; Emed J; Roussin A; Tagalakis V; Morris M; Geerts W
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD008201. PubMed ID: 29687454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
    Mai V; Bertoletti L; Cucherat M; Jardel S; Grange C; Provencher S; Lega JC
    PLoS One; 2019; 14(4):e0214134. PubMed ID: 30933993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
    Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
    Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.